Sally Horne, MD
Neurology · Chattanooga, TNNPI 1215040381
Payments from drug & device makers
Across 150 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$763
- AbbVie$613
- Biohaven Pharmaceuticals, Inc.$316
- EMD Serono, Inc.$204
- Greenwich Biosciences, Inc.$158
- Novartis$129
- plus $876 from 22 others
What the payments were for
- Consulting fees$60020%
- Food & beverage$2,37578%
- Education$833%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 11 | $763 |
| AbbVie(2 entities) | 53 | $613 |
| Biohaven Pharmaceuticals, Inc. | 21 | $316 |
| EMD Serono, Inc. | 7 | $204 |
| Greenwich Biosciences, Inc. | 4 | $158 |
| Novartis | 7 | $129 |
| SK Life Science, Inc. | 2 | $104 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $83 |
| Supernus Pharmaceuticals, Inc. | 6 | $81 |
| Teva Pharmaceuticals USA, Inc. | 5 | $78 |
| Amgen(2 entities) | 4 | $69 |
| Sanofi | 2 | $67 |
| UCB, Inc. | 4 | $66 |
| Acadia Pharmaceuticals Inc | 3 | $46 |
| Johnson & Johnson | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Catalyst Pharmaceuticals, Inc. | 1 | $26 |
| Banner Life Sciences, LLC | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Medtronic | 1 | $20 |
| TG Therapeutics, Inc. | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Smith+Nephew | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,058 in reported general payments places this provider in the 50th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AmpyraDalfampridine | 12 | $47,952 |
| Dimethyl Fumarate | 11 | $41,645 |
| Dalfampridine ErDalfampridine | 44 | $29,624 |
| Baclofen | 47 | $1,015 |
| Phenytoin Sodium Extended | 16 | $662 |
| Levetiracetam | 26 | $432 |
| RizatriptanRizatriptan Benzoate | 16 | $399 |
| Sumatriptan Succinate | 14 | $78 |
| Cyclobenzaprine Hcl | 21 | $57 |
Paid to pharmacies, not to this prescriber.
Other neurology in Chattanooga
- Thomas DevlinChattanooga$288K
- David RankineChattanooga$167K
- Tareck KadrieChattanooga$150K
- Lee SteinCordova$22.6M
- Sibyl WrayKnoxville$21.6M
- Lora McGillMemphis$7.5M
- Thomas ArnoldCordova$5.5M
- Daniel ClaassenNashville$3.5M
- Samuel HunterSpring Hill$2.9M
- Randall TrudellKnoxville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.